@article{ref1,
title="Extended-release naltrexone to prevent opioid relapse in criminal justice offenders",
journal="New England journal of medicine",
year="2016",
author="Lee, Joshua D. and Friedmann, Peter D. and Kinlock, Timothy W. and Nunes, Edward V. and Boney, Tamara Y. and Hoskinson, Randall A. Jr. and Wilson, Donna and McDonald, Ryan and Rotrosen, John and Gourevitch, Marc N. and Gordon, Michael and Fishman, Marc and Chen, Donna T. and Bonnie, Richard J. and Cornish, James W. and Murphy, Sean M. and O'Brien, Charles P.",
volume="374",
number="13",
pages="1232-1242",
abstract="Opioid-use disorder is a chronic relapsing condition that has serious public health consequences. Opioid dependence disproportionately affects U.S. criminal justice system populations, and relapse and overdose deaths occur at high rates after release from incarceration.1 Evidence-based opioid-agonist maintenance therapies for opioid dependence (methadone and buprenorphine) are effective in prison, jail, and community reentry (i.e., parole) settings2-5 but have historically been unavailable or discouraged among criminal justice clients.6-8 Extended-release naltrexone (Vivitrol, Alkermes), a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, was approved by the Food and Drug Administration in 2010 for the prevention of relapse to. . .<p /> <p>Language: en</p>",
language="en",
issn="0028-4793",
doi="10.1056/NEJMoa1505409",
url="http://dx.doi.org/10.1056/NEJMoa1505409"
}